Search Results
Sep 08, 2026, 08:17 ET HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study
pharmacodynamic activity of HBM9378/WIN378 in patients with uncontrolled moderate-to-severe asthma. The study also evaluates the effects of HBM9378/WIN378 on lung function and biomarkers of airway inflammation and informed dose selection for Phase 3 development. The Phase 2 portion of the study enrolled a total
More news about: Harbour BioMed
Sep 08, 2026, 08:00 ET Brainomix and Endeavor BioMedicines Present Positive Results from Quantitative Image Analysis of Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Trial at ERS Congress
demonstrated that treatment with taladegib improved lung function from baseline as measured by forced vital capacity (FVC), increased total lung capacity and reversed measures of interstitial lung disease (ILD) from baseline at Week 12.Brainomix 360 e-Lung is an FDA-cleared, CE-marked AI-powered image
More news about: Brainomix
Sep 08, 2026, 08:00 ET Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
help educate families about protection against a serious respiratory syncytial virus (RSV) lung infectionBEYFORTUS has been chosen by millions of parents to help protect their babies from serious RSV lung infection, a leading cause of hospitalization among babies under 1 year of ageCampaign
More news about: Sanofi
Sep 08, 2026, 08:00 ET Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Acclaim-3 clinical trials for non-small cell lung cancer and small cell lung cancer, respectively. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to both lung cancer programs and Orphan Drug designation to the small cell lung cancer program.Genprex's preclinical
More news about: Genprex, Inc.
Sep 08, 2026, 08:00 ET Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
pharmacodynamic activity of SKB378/WIN378 in patients with uncontrolled moderate-to-severe asthma. The study also evaluates the effects of SKB378/WIN378 on lung function and biomarkers of airway inflammation and informed dose selection for Phase 3 development. The Phase 2 portion of the study enrolled a total
More news about: Kelun-Biotech
Sep 08, 2026, 07:30 ET Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
non-small cell lung cancer (NSCLC), with initial results targeted by mid-2027. This readout is expected to provide important clinical insights to inform future development, demonstrating the potential for INBRX-106 to extend well beyond head and neck cancer into not only perioperative lung cancer, but broader
More news about: Inhibrx Biosciences, Inc.
Sep 07, 2026, 21:00 ET Infinix ra mắt toàn cầu XPAD 30 Pro: Người bạn đồng hành tối ưu toàn diện cho việc học tập và giải trí của giới trẻ
hứng từ phong cách Bauhaus và Mondrian với lớp hoàn thiện cao cấp mang vẻ ngoài như kính. Ăng-ten ẩn giúp duy trì khả năng thu sóng mạnh mẽ trên mặt lưng kim loại bóng bẩy. Có ba phiên bản màu Twilight Purple, Anthracite Grey và Titanium Silver, máy tính bảng kết hợp vẻ đẹp nổi bật với độ bền vượt trội,
More news about: Infinix
Sep 07, 2026, 05:42 ET Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
China.About Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis is a chronic, scarring lung disease characterized by progressive and irreversible decline in lung function. Affecting approximately 5 million people worldwide, IPF carries a poor prognosis with a median survival
More news about: Insilico Medicine
Sep 05, 2026, 08:57 ET Signant Health and Lothar Medical Sign Letter of Intent to Commercialize ALDS PRO for Clinical Trials
respiratory diagnostic technologies designed to make lung assessment faster, more comprehensive, and easier to perform. Its portable ALDS platform combines respiratory measurements with cloud-based analysis to support efficient, multidimensional lung-function assessment. ALDS PRO integrates airway oscillometry,
More news about: Signant Health
Sep 04, 2026, 17:05 ET Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3
More news about: Actinium Pharmaceuticals, Inc.
Sep 04, 2026, 10:30 ET Clinical Trials Services Market worth $97.41 billion by 2031 - Exclusive Report by MarketsandMarkets™
Contract Research Organization (CRO) Services Market Market by Type (Early Phase, Clinical, Lab, Consulting), Therapeutic Area [Oncology (Breast, Lung), Infectious, Neurology, Vaccines], Modality, Model (FSO, FSP), End User, Competition - Global Forecast to 2031
More news about: MarketsandMarkets
Sep 04, 2026, 07:00 ET Withings Introduces StethO Sense, Bringing Heart and Lung Sound Analysis to BeamO
WorksFrom the StethO Sense section of the Withings+ app, users can select a heart or lung recording and instantly start the analysis. Heart recordings are taken at one of four standard positions, while lung recordings are taken at up to eight positions at 12 years of age and above, and six positions
More news about: Withings
Sep 04, 2026, 07:00 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and
More news about: Insmed Incorporated
Sep 03, 2026, 15:00 ET 'NORMAL' PSA ISN'T ALWAYS 'OK,' NOTES PROTON THERAPY PROVIDER MARKING NATIONAL PROSTATE CANCER AWARENESS MONTH
opened in March 2012 as the tri-state region's first proton therapy facility, treating a range of cancers including diseases of the prostate, breast, lung, brain, head and neck, and gastrointestinal system, as well as sarcomas and many pediatric cases. Using the most advanced radiation treatment available,
More news about: ProCure Proton Therapy Center
Sep 03, 2026, 09:25 ET Zendure giới thiệu Agentic HEMS tại IFA 2026: "Trung tâm năng lượng gia đình của kỷ nguyên AI"
vững, Zendure là đơn vị tiên phong toàn cầu về HEMS dạng cắm. Với các trung tâm R&D và vận hành trải rộng khắp các trung tâm công nghệ lớn như Thung lũng Silicon và Khu vực Vịnh lớn, cùng với Nhật Bản và Đức, tầm nhìn của chúng tôi là trở thành Trung tâm năng lượng gia đình của kỷ nguyên AI. Sứ mệnh của
More news about: Zendure
Sep 03, 2026, 08:09 ET Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)
disease.Comprehensive Improvement in Composite Metrics: The primary outcome was a rigorous composite of clinical worsening events, defined as death, heart or lung transplantation, hospitalization for heart failure, outpatient worsening of heart failure leading to intravenous diuresis, or a significant decline
More news about: Pulnovo Medical
Sep 03, 2026, 08:00 ET Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Sep 03, 2026, 07:53 ET Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)
disease.Comprehensive Improvement in Composite Metrics: The primary outcome was a rigorous composite of clinical worsening events, defined as death, heart or lung transplantation, hospitalization for heart failure, outpatient worsening of heart failure leading to intravenous diuresis, or a significant decline
More news about: Pulnovo Medical
Sep 03, 2026, 07:00 ET Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.Patients are encouraged
More news about: Insmed Incorporated
Sep 03, 2026, 07:00 ET CytoSorbents Announces Reverse Stock Split
blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: Cytosorbents Corp
Sep 02, 2026, 17:00 ET Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (TPS ≥1%).Detailed data from the interim OS analysis will be presented at an upcoming international
More news about: Akeso, Inc.
Sep 02, 2026, 11:00 ET FCANCER CELEBRATES LANDMARK 100TH EVENT WITH HOST NICOLE "SNOOKI" POLIZZI, PERFORMANCES FROM DILLON FRANCIS, DIPLO & DJ PAULY D, MARKING YEARS OF IMPACT IN CANCER PREVENTION
navigators in high-risk communities to connect patients with HPV vaccines to prevent cancer and screenings to find breast, cervical, colorectal, and lung cancer early.Offering tangible and emotional support programs to make life with cancer easier.Working hard to help people take control
More news about: FCancer
Sep 02, 2026, 08:30 ET Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
the Caris Precision Oncology Alliance® (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, South Korea. Caris research includes two mini oral presentations,
More news about: Caris Life Sciences
Sep 02, 2026, 07:28 ET CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the
More news about: CytoSorbents Corporation
Sep 02, 2026, 05:03 ET What To Expect After Your Doctor Finds a Lung Nodule
greatest opportunities to improve lung cancer outcomes is the early identification and management of lung nodules, or small spots on lung imaging, that can sometimes be an early sign of lung cancer. More than half of lung nodule cases lack proper follow-up, and while most lung nodule findings do not end up
More news about: American Lung Association